Russia's Veropharm increases profit by 14% in nine months
This article was originally published in Scrip
Executive Summary
The net profits of Veropharm, one of Russia's largest manufacturers of generic drugs and anticancers, rose by 14% to Rb834 million ($26.6 million) in the first nine months of this year; its sales were up by 22% to Rb3.9 billion compared with the same period of 2009.